혈액종양 입원 환자 대상 임상약사의 처방중재활동 및 회피비용 분석
Cost Avoidance and Clinical Pharmacist Interventions on Hospitalized Patients in Hematologic malignancies
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Patients with hematologic cancers have a risk of drug-related problems (DRPs) from medications associated withchemotherapy and supportive care. Although the role of oncology pharmacists has been widely documented in the literature, fewstudies have reported its impact on cost reduction. This study aimed to describe the activities of oncology pharmacists with respect tohematologic diseases and evaluate the associated cost avoidance. Methods: From January to July 2021, patients admitted to thedepartment of hemato-oncology at Seoul National University, Bundang Hospital were studied. The activities of oncologypharmacists were reported by DRP type following the Pharmaceutical Care Network version 9.1 guidelines, and the acceptance ratewas calculated. The avoided cost was estimated based on the cost of the pharmacy intervention, pharmacist manpower, andprescriptions associated with the intervention. Results: Pharmacists intervened in 584 prescriptions from 208 patients during thestudy period. The most prevalent DRP was “adverse drug event (possibly) occurring” (32.4%), followed by “effect of drug treatmentnot optimal” (28.6%). “Drug selection” (42.5%) and “dose selection” (30.3%) were the most common causes of DRPs. Theacceptance rate of the interventions was 97.1%. The total avoidance cost was KRW 149,468,321; the net profit of the avoidance cost,excluding labor costs, was KRW 121,051,690; and the estimated cost saving was KRW 37,223,748. Conclusion: Oncologypharmacists identified and resolved various types of DRPs from prescriptions for patients with hematologic disease, by reviewingthe prescriptions. Their clinical service contributed to enhanced patient safety and the avoidance of associated costs.
Abstract
Background: Patients with hematologic cancers have a risk of drug-related problems (DRPs) from medications associated withchemotherapy and supportive care. Although the role of oncology pharmacists has been widely documented in the literature, fewstudies have reported its impact on cost reduction. This study aimed to describe the activities of oncology pharmacists with respect tohematologic diseases and evaluate the associated cost avoidance. Methods: From January to July 2021, patients admitted to thedepartment of hemato-oncology at Seoul National University, Bundang Hospital were studied. The activities of oncologypharmacists were reported by DRP type following the Pharmaceutical Care Network version 9.1 guidelines, and the acceptance ratewas calculated. The avoided cost was estimated based on the cost of the pharmacy intervention, pharmacist manpower, andprescriptions associated with the intervention. Results: Pharmacists intervened in 584 prescriptions from 208 patients during thestudy period. The most prevalent DRP was “adverse drug event (possibly) occurring” (32.4%), followed by “effect of drug treatmentnot optimal” (28.6%). “Drug selection” (42.5%) and “dose selection” (30.3%) were the most common causes of DRPs. Theacceptance rate of the interventions was 97.1%. The total avoidance cost was KRW 149,468,321; the net profit of the avoidance cost,excluding labor costs, was KRW 121,051,690; and the estimated cost saving was KRW 37,223,748. Conclusion: Oncologypharmacists identified and resolved various types of DRPs from prescriptions for patients with hematologic disease, by reviewingthe prescriptions. Their clinical service contributed to enhanced patient safety and the avoidance of associated costs.
참고문헌 (32)
- 이제중, "최근 국내에서 증가하는 혈액질환", 대한내과학회지, 78(5), pp.557~563 (2010), 대한내과학회
- Serrano-Fabiá A, "Multidisciplinary system for detecting medication errors in antineoplastic chemotherapy", J Oncol Pharm Pract, 16(2), pp.105~112 (2010)
- Prot-Labarthe S, "Pharmaceutical care in an inpatient pediatric hematopoietic stem cell transplant service", J Oncol Pharm Pract, 14(3), pp.147~152 (2008)
- Dormann, H., "Incidence and Costs of Adverse Drug Reactions During Hospitalisation", Drug Safety, 22(2), pp.161~168 (2000)
- Lee EJ, "Polypharmacy and inappropriate medications in older adults", The Korean Association Of Internal Medicine autumn conference, 25 (2013)
- Cho YS, "Management of adverse drug events with polypharmacy in older patients", JKSHP, 28(3), pp.219~221 (2011)
- Leger DY, "Polypharmacy, potentially inappropriate medications and drug-drug interactions in geriatric patients with hematologic malignancy: observational single-center study of 122 patients", J Geriatr Oncol, 9(1), pp.60~67 (2018)
- Balk TE, "Drug-drug interactions in pediatric oncology patients", Pediatr Blood Cancer, 64(7), pp.26410~ (2017)
- Delpeuch A, "Impact of clinical pharmacy services in a hematology", oncology inpatient setting, 2015, pp.35(1), 457~460
- Chen PZ, "Clinical and economic impact of clinical pharmacist intervention in a hematology unit", J Oncol Pharm Pract, 26(4), pp.866~872 (2020)
- 정채린, "혈액종양환자에서의 약물관련문제 분석과 이에 대한 임상약사의 중재 가치 평가", 석사, 약학과 예방·임상약학전공, pp.2014
- 유지선, "혈액내과 임상약사의 처방중재 활동 평가", 병원약사회지, 37(4), pp.429~443 (2020), 한국병원약사회[DOI]
- "PCNE classification for drug-related problems"[URL]
- "ATC/DDD Index 2022"[URL]
- Park BG, "Clinical and economic impact of medication reconciliation by designated ward pharmacists in a hospitalist-managed acute medical unit", Res Social Adm Pharm, 18(4), pp.2683~2690 (2022)
- Eichenberger PM, "Classification of drug-related problems with new prescriptions using a modified PCNE classification system", Pharm World Sci, 32(3), pp.362~372 (2010)
- Jamal I, "Pharmacist's interventions in reducing the incidences of drug related problems in any practice setting", International current pharmaceutical journal, 4(2), pp.347~352 (2015)
- Nielsen TRH, "Clinical pharmacist service in the acute ward", Int J Clin Pharm, 35(6), pp.1137~1151 (2013)
- van Mil JF, "Drugrelated problem classification systems", Ann Pharmacother, 38(5), pp.859~867 (2004)
- 김귀숙, "항암치료에서 약사처방중재의 경제적 편익분석", 약 학 회 지, 64(3), pp.219~225 (2020), 대한약학회[DOI]
- Koo HK, "Effects of adverse drug reactions detected using monitoring program on the length of stay and charges in the hospital setting", doctor, pp.2009
- The Korean Society of Health-System Pharmacists, "Hospital pharmacy leadership education series, Korea" (2021)
- Taplitz RA, "Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression : ASCO and IDSA clinical practice guideline update", J Clin Oncol, 36(30), pp.3043~3054 (2018)
- "Mabthera®"[URL]
- "Darzalex®"[URL]
- Oliveira CS, "Impact of clinical pharmacy in oncology and hematology centers : A systematic review", J Oncol Pharm Pract, 27(3), pp.679~692 (2021)
- Moukafih B, "Impact of clinical pharmacy services in a hematology", oncology ward in Morocco, 2021, pp.27(2), 305~311
- 이소영, "국내 병원약사의 중재활동과 성과에 대한 체계적 문헌고찰", 한국임상약학회지, 29(3), pp.193~201 (2019), 한국임상약학회[DOI]
- Kim HT, "Clinical and economic effects of pharmaceutical care : A systematic review", Journal of Korean Academy of Social & Managed Care Pharmacy, 7(1), pp.39~51 (2019)
- Waddell JA, "Pharmacy staffinterventions in a medical center hematologyoncology service", J Am Pharm Assoc(Wash), 38(4), pp.451~456 (1998)
- Wu HT, "Clinical pharmacy in an inpatient leukemia and bone marrow transplant service", Am J Health Syst Pharm, 62(7), pp.744~747 (2005)
- Han JM, "Clinical and economic impact of pharmacists’ intervention in a large volume chemotherapy preparation unit", Int J Clin Pharm, 38(5), pp.1124~1132 (2017)